<?xml version="1.0" ?>
<document id="f3de553d9173bab4ad066e7d00994c165a7d9a41">
  <chunk id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c0" text="The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action">
    <entity charOffset="70-76" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c0.e0" ontology_id="CHEBI_5133" text="Action" type="chemical"/>
  </chunk>
  <chunk id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1" text="The HLA region encodes several molecules that play key roles in the immune system. Strong association between the HLA region and autoimmune disease (AID) has been established for over fifty years. Association of components of the HLA class II encoded HLA-DRB1-DQA1-DQB1 haplotype has been detected with several AIDs, including rheumatoid arthritis, type 1 diabetes and Graves' disease. Molecules encoded by this region play a key role in exogenous antigen presentation to CD4+ Th cells, indicating the importance of this pathway in AID initiation and progression. Although other components of the HLA class I and III regions have also been investigated for association with AID, apart from the association of HLA-B*27 with ankylosing spondylitis, it has been difficult to determine additional susceptibility loci independent of the strong linkage disequilibrium (LD) with the HLA class II genes. Recent advances in the statistical analysis of LD and the recruitment of large AID datasets have allowed investigation of the HLA class I and III regions to be re-visited. Association of the HLA class I region, independent of known HLA class II effects, has now been detected for several AIDs, including strong association of HLA-B with type 1 diabetes and HLA-C with multiple sclerosis and Graves' disease. These results provide further evidence of a possible role for bacterial or viral infection and CD8+ T cells in AID onset. The advances being made in determining the primary associations within the HLA region and AIDs will not only increase our understanding of the mechanisms behind disease pathogenesis but may also aid in the development of novel therapeutic targets in the future.">
    <entity charOffset="31-40" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e0" ontology_id="CHEBI_25367" text="molecules" type="chemical"/>
    <entity charOffset="386-395" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e1" ontology_id="CHEBI_25367" text="Molecules" type="chemical"/>
    <entity charOffset="430-434" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e2" ontology_id="CHEBI_50906" text="role" type="chemical"/>
    <entity charOffset="448-455" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e3" ontology_id="CHEBI_59132" text="antigen" type="chemical"/>
    <entity charOffset="521-528" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e4" ontology_id="CHEBI_34922" text="pathway" type="chemical"/>
    <entity charOffset="1357-1361" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e5" ontology_id="CHEBI_50906" text="role" type="chemical"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e0" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e1" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p0" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e0" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e2" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p1" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e0" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e3" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p2" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e0" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e4" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p3" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e0" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e5" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p4" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e1" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e2" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p5" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e1" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e3" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p6" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e1" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e4" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p7" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e1" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e5" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p8" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e2" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e3" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p9" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e2" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e4" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p10" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e3" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e4" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p11" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e3" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e5" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p12" relation="true"/>
    <pair e1="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e4" e2="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.e5" id="f3de553d9173bab4ad066e7d00994c165a7d9a41.c1.p13" relation="true"/>
  </chunk>
</document>
